United States

Grifols SA (GRLS.MC)

GRLS.MC on Madrid SE C.A.T.S.

6:17am EST
Change (% chg)

€-0.14 (-0.70%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for GRLS.MC


Grifols SA is a Spain-based company engaged in the biopharmaceuticals manufacture. The Company’s activities are divided into four business segments: Bioscience, Hospital, Diagnostic and Raw materials. The Bioscience division focuses on the research, development, manufacturing and marketing of products derived from human plasma... (more)


Beta: 0.14
Market Cap(Mil.): €13,194.69
Shares Outstanding(Mil.): 687.55
Dividend: 0.18
Yield (%): 1.50


  GRLS.MC Industry Sector
P/E (TTM): 40.15 28.84 29.63
EPS (TTM): 0.52 -- --
ROI: 6.37 13.44 12.96
ROE: 15.96 14.34 14.11

BRIEF-Spain's Grifols says has concluded debt refinancing for $6.3 bln

* Says it has concluded the debt refinancing process it started on Jan. 9 and has refinanced debt for $6.3 billion

Feb 06 2017

BRIEF-Grifols buys 49 pct in US-based Access Biologicals for $51 million

* Invests in US-based Access Biologicals via acquisition of 49 percent of its voting rights for $51 million

Jan 12 2017

BRIEF-Grifols starts refinancing of part of its bank debt

* Starts refinancing process of part of its bank debt for a total amount of $6.3 billion

Jan 10 2017

Grifols to buy Hologic's stake in blood screening JV for $1.85 billion

Spain's Grifols SA , which develops plasma protein therapies, said it would buy U.S. medical device maker Hologic Inc's interest in their blood screening joint venture for $1.85 billion in cash.

Dec 14 2016

BRIEF-Grifols 9-month net profit rises to 406.1 mln euros

* 9-month net profit 406.1 million euros ($448.5 million)versus 401.6 million euros year ago

Nov 08 2016

BRIEF-Oncbiomune signs term sheet to acquire Vitel Laboratorios, S.A. De C.V.

* Oncbiomune signs term sheet to acquire Vitel Laboratorios, s.a. De c.v. Source text for Eikon: Further company coverage:

Nov 03 2016

BRIEF-Grifols to pay FY 2016 interim dividend of 0.18 euro/shr

* Says to pay interim dividend for 2016 of 0.18 euro ($0.1972) per share on Dec. 7 Source text for Eikon: Further company coverage: ($1 = 0.9127 euros) (Gdynia Newsroom)

Oct 31 2016

BRIEF-Medica Sur receives green light to buy LMP

* Said on Wednesday received an approval from a competition watchdog to acquire Laboratorio Medico Polanco (LMP) and its units Laboratorios Clinicos de Puebla (LCP), Laboratorios Clinicosde Puebla en Bioequivalencia (LCPB) and other units

Oct 06 2016

BRIEF-Prim buys branches from Laboratorios Milo for fixed price of 1.2 mln euros

* Buys pharmacy, orthopedics and podiatry branches from Laboratorios Milo for 1.24 million euros ($1.39 million) and variable price depending on results of the branches in 2016-2020 Source text for Eikon:

Sep 12 2016

More From Around the Web

Earnings vs. Estimates